Autopsy report · NCT03139370
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
Cause of deathFunding or business
“The study was terminated due to the sponsor's decision to discontinue the clinical trial.”
Life of this trial
- Registered 8 months before it started.
- Ran for about 5 years 5 months before it stopped.
- 16 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Kite, A Gilead Company
- Sponsor type
- Industry
- Conditions
- Solid Tumor
- Interventions
- KITE-718; Cyclophosphamide; Fludarabine; MAGE - A3/A6 Screening Test
- Participants
- 16
- Sites
- 12
- Countries
- United States
Trials that died the same way
- Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma
“The study was terminated voluntarily by the sponsor due to changes in clinical development strategy.” - A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
“The study was terminated by sponsor for reasons of adjusted clinical development strategy.” - Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
“Termination of the clinical trial by sponsor.” - Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip
“The Sponsor terminated the study.” - Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
“This study was terminated by the Sponsor.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.